|
KMID : 1009020220200040762
|
|
Clinical Psychopharmacology and Neuroscience
2022 Volume.20 No. 4 p.762 ~ p.767
|
|
|
Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later
|
|
Gasnier Matthieu
Choucha Walid
Montani David
Noel Nicolas
Verstuyft Celine
Radiguer Francois
Monnet Xavier
Becquemont Laurent
Corruble Emmanuelle
Colle Romain
|
|
|
Abstract
|
|
|
Objective: Psychiatric symptoms and mental disorders are common after Coronavirus Disease-19 (COVID-19). Some drugs used to treat acute COVID-19 have psychiatric side effects. We assessed the psychiatric symptoms and mental disorders of patients treated for acute COVID-19 with hydroxychloroquine (HCQ), interleukin-6 receptor antagonists (anti-IL-6), and corticoids (CTC).
Methods: We evaluated 177 patients in a day hospital 4 months after acute infection.
Results: In a multivariate analysis, HCQ was associated with significant anxiety symptoms (odds ratio [OR] = 5.9, 95% confidence interval [95% CI] = 1.8?20.0, p = 0.003) and mental disorders (OR = 4.1, 95% CI = 1.2?13.9, p = 0.02). In a bivariate analysis with propensity matched cohorts, HCQ was associated with significant anxiety symptoms (9 patients [50.0%] with significant symptoms in the HCQ group versus 15 [20.1%] in the control group, OR = 3.8, 95% CI = 1.3?11.3, p = 0.01). Anti-IL-6 and CTC were not associated with significant psychiatric symptoms or mental disorders.
Conclusion: We recommend monitoring psychiatric symptoms, especially anxiety, in patients treated with HCQ during COVID-19 infection. Further studies with larger samples and prospective assessments are needed to confirm our results.
|
|
|
KEYWORD
|
|
|
Major depressive disorder, Anxiety, COVID-19
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|